DISEASE INDICATIONS: Psoriasis

MANUFACTURER: Almirall, S.A.

USAGE: Subcutaneous

MEDICINE APPROVED BY:

European Medical Agency (EMA)

Food and Drug Administration (FDA)

Ilumya (tildrakizumab) is a biologic medication used to treat moderate-to-severe plaque psoriasis in adults. It works by blocking the activity of the protein IL-23, which reduces inflammation and scaling in the affected skin.